BYSI
BeyondSpring Inc. Ordinary Shares
Nasdaq · usd
BeyondSpring Inc. Ordinary Shares (BYSI) trades at $0.5599 (-3.27%) as of 4:29:19 PM EST on Nov 17, 2026, +9.16% over the past month. Market cap is $23.97M, with 41.9 days to cover in short interest.
Stock performance
How BeyondSpring Inc. Ordinary Shares (BYSI) stock has performed from one day to one year, with its 52-week range.
- 1D
- -3.27%
- 1W
- -3.42%
- 1M
- +9.16%
- YTD
- -65.65%
- 1Y
- -71.29%
- 52-wk range
- $0.42 – $2.44
Key statistics
Today's trading snapshot for BYSI: day range, open, previous close, volume and market cap.
- Day range
- $0.56 – $0.59
- Open
- $0.58
- Prev close
- $0.58
- Volume
- 13.62K
- Market cap
- $23.97M
- Shares out
- 41.12M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for BeyondSpring Inc. Ordinary Shares: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- -0.68
- P/FCF
- —
- ROE
- 18.8%
- ROA
- -45.8%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 16, 2026
8-K filings
Material corporate events BeyondSpring Inc. Ordinary Shares has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 13, 2026
On November 13, 2026, BeyondSpring Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.
- Partnership or collaborationOct 6, 2026
Pursuant to the terms and subject to the conditions set forth in the Purchase and Collaboration Agreement, the Parties established a strategic collaboration with respect to certain development activities involving the conduct and completion of the China portion of DUBLIN-4, a global Phase 3 trial of Plinabulin in combination with docetaxel.
- Listing deficiency noticeOct 2, 2026
On September 29, 2026, BeyondSpring Inc. received a written notification from Nasdaq notifying the Company that, because the Company's market value of listed securities ("MVLS") has fallen below $35 million for the last 30 consecutive business days, the Company no longer complies with the MVLS requirement for continued listing on the Nasdaq Capital Market.
- Divestiture agreementSep 29, 2026
On September 28, 2026, BeyondSpring Inc. entered into a Share Purchase and Collaboration Agreement ... to sell and transfer to the Investor the entire issued share capital in BeyondSpring Ltd., a direct wholly owned subsidiary of the Company.
- Listing deficiency noticeSep 18, 2026
On September 17, 2026, BeyondSpring Inc. (the "Company") received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that, because the closing bid price for the Company's ordinary shares ... has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
BYSI short interest
How heavily BYSI is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 41.9
- Short interest
- 2.28M
- Avg volume
- 54.38K
As of · reported to FINRA twice monthly.
BYSI news
The latest news and headlines about BeyondSpring Inc. Ordinary Shares (BYSI).
- BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration PathpositiveGlobeNewswire Inc.· Dec 12, 2025
- SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New InvestorsneutralGlobeNewswire Inc.· Jan 28, 2025
- BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational StudiespositiveGlobeNewswire Inc.· Jan 28, 2025
- BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual MeetingpositiveGlobeNewswire Inc.· Nov 11, 2024
- BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024positiveGlobeNewswire Inc.· Sep 16, 2024
Frequently asked questions
What is the BeyondSpring Inc. Ordinary Shares (BYSI) stock price today?
BeyondSpring Inc. Ordinary Shares (BYSI) is trading at $0.5599 (-3.27% on the day) as of 4:29:19 PM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is BeyondSpring Inc. Ordinary Shares?
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
What is the short interest in BYSI?
As of Oct 30, 2026, BYSI has 2.28M shares short and 41.9 days to cover.
What exchange is BYSI listed on?
BeyondSpring Inc. Ordinary Shares (BYSI) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of BYSI with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a BYSI analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.